Lozano-Calderon Santiago A, Clunk Marilee J, Gonzalez Marcos R, Sodhi Alisha, Krueger Ryan K, Gruender Allison C, Greenberg David D
Musculoskeletal Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts.
University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
JB JS Open Access. 2024 Jul 10;9(3). doi: 10.2106/JBJS.OA.23.00148. eCollection 2024 Jul-Sep.
Minimally invasive surgical interventions for metastatic invasion of the pelvis have become more prevalent and varied. Our group hypothesized that the use of percutaneous photodynamic nails (PDNs) would result in decreased pain, improved functional outcomes and level of ambulation, and decreased use of opioid pain medication.
We performed a retrospective chart review of patients with metastatic pelvic bone disease undergoing stabilization with PDNs (IlluminOss Medical) at 2 institutions. Functional outcome measures assessed include the Combined Pain and Ambulatory Function (CPAF), Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function, and PROMIS Global Health-Physical. Pain was assessed using a visual analog scale (VAS). Outcomes were assessed preoperatively and at 6 weeks, 3 months, 6 months, and 1 year following surgery.
A total of 39 patients treated with PDNs were included. No cases of surgical site infection or implant failure were identified. The median pain VAS score decreased from 8 preoperatively to 0 at the 6-week time point (p < 0.0001). The median CPAF score improved from 5.5 points preoperatively to 7 points at the 3-month mark (p = 0.0132). A significant improvement in physical function was seen at 6 months in the PROMIS Physical Function (p = 0.02) and at both 6 months (p = 0.01) and 1 year (p < 0.01) for the PROMIS Global Health-Physical. The rate of patients prescribed opioid analgesia dropped from 100% preoperatively to 20% at 6 months following surgery (p < 0.001). By 6 weeks, all patients were fully weight-bearing and able to walk independently with or without assistive devices.
Percutaneous stabilization of metastatic periacetabular defects using PDNs is a safe and effective palliative procedure that has been shown to improve patient mobility and provide early pain relief.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
针对骨盆转移瘤侵袭的微创外科干预措施已变得更加普遍和多样。我们的团队推测,使用经皮光动力钉(PDN)将减轻疼痛、改善功能结局和行走能力,并减少阿片类止痛药物的使用。
我们对两家机构中接受PDN(IlluminOss Medical)稳定治疗的骨盆转移性骨病患者进行了回顾性病历审查。评估的功能结局指标包括疼痛与行走功能综合评分(CPAF)、患者报告结局测量信息系统(PROMIS)身体功能评分以及PROMIS全球健康-身体评分。使用视觉模拟量表(VAS)评估疼痛。在术前以及术后6周、3个月、6个月和1年评估结局。
共纳入39例接受PDN治疗的患者。未发现手术部位感染或植入物失败的病例。疼痛VAS评分中位数从术前的8分降至6周时的0分(p < 0.0001)。CPAF评分中位数从术前的5.5分提高到3个月时的7分(p = 0.0132)。PROMIS身体功能评分在6个月时显著改善(p = 0.02),PROMIS全球健康-身体评分在6个月(p = 0.01)和1年(p < 0.01)时均显著改善。接受阿片类镇痛药物治疗的患者比例从术前的100%降至术后6个月时的20%(p < 0.001)。到6周时,所有患者均完全负重,能够独立行走,无论是否使用辅助设备。
使用PDN经皮稳定髋臼周围转移性缺损是一种安全有效的姑息性手术,已被证明可改善患者活动能力并提供早期疼痛缓解。
治疗性四级。有关证据级别的完整描述,请参阅作者指南。